Treatment Details – 4.9 months
|Patients: This Phase II study involved 27 patients with malignant mesothelioma.|
Treatment: The treatment consisted of the administration of the chemotherapy drug, capecitabine (xeloda),
Toxicity: One patient died of treatment related diarrhea, dehydration, fever and neutropenia. Other grade 3-4 toxicities included hematologic, hypertension, fatigue, dermatological, anorexia, dehydration, diarrhea, nausea, stomatitis/pharyngitis, infection, and pain.
Results: Median survival was 4.9 months.
Correspondence: Gregory A. Otterson, MD